Long Term Follow up of Patients Who Were Treated With Extracorporeal Membrane Oxygenation for Pandemic Influenza A/H1N1 Induced Severe Respiratory Failure

Patients treated with Extracorporeal Membrane Oxygenation (ecmo) for severe respiratory or circulatory failure show severe long term disability due to impaired lung -, cerebral-, cognitive function and impaired quality of life. This study investigates the long term outcome of all patients who are still alive three years after ECMO treatment for severe respiratory failure during the H1N1 2009 pandemic at the Karolinska University Hospital.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Long Term Outcome Acute Lung Injury Lung Diseases Lung Injury Respiratory Tract Diseases

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Karolinska University Hospital

Stockholm, 17176, Sweden

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Survivors of ECMO treatment for influenza a/h1n1 pneumonia during 2009/2010 pandemics at the ECMO Center Karolinska

Exclusion criteria

None

Treatment and study plan

CT Scan

Radiation

Cognitive function

Behavioral

MRI

Radiation

Primary outcomes

Lung function

Time frame: 3 years after ecmo treatment

Sponsors and collaborators

Lead sponsor

Karolinska University Hospital

Other

Collaborators

Karolinska Institutet
Uppsala University Hospital

Registry information

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Jan 8, 2013
Registry last updated: Nov 21, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting